TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
4.380
+0.050 (1.15%)
Jul 29, 2026, 4:00 PM EDT - Market closed
TriSalus Life Sciences Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 56.55 | 20.44 | 8.53 | 11.78 | 9.41 | 250.21 |
Cash & Short-Term Investments | 56.55 | 20.44 | 8.53 | 11.78 | 9.41 | 250.21 |
Cash Growth | 335.02% | 139.75% | -27.61% | 25.10% | -96.24% | -0.45% |
Accounts Receivable | 5.22 | 6.56 | 5.09 | 3.55 | 1.56 | - |
Inventory | 3.78 | 3.08 | 4.05 | 2.55 | 1.47 | - |
Other Current Assets | 2.59 | 2.17 | 3.01 | 2.99 | 4.77 | 0.33 |
Total Current Assets | 68.14 | 32.24 | 20.67 | 20.86 | 17.21 | 0.53 |
Net Property, Plant & Equipment | 2.77 | 2.67 | 2.88 | 3.27 | 3.61 | - |
Other Intangible Assets | - | - | - | - | 0.8 | - |
Other Long-Term Assets | 0.07 | 0.42 | 0.42 | 0.47 | 0.37 | - |
Total Assets | 70.98 | 35.33 | 23.97 | 24.6 | 22 | 250.53 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 4.23 | 3 | 2.27 | 3.39 | 4.95 | 1.06 |
Accrued Expenses | 7.07 | 8.1 | 7.36 | 10.56 | 6.38 | - |
Short-Term Debt | - | - | - | - | - | 0.54 |
Current Portion of Leases | 0.22 | 0.17 | 0.22 | 0.35 | 0.37 | - |
Other Current Liabilities | 0.27 | 0.23 | 0.38 | 0.39 | 20.66 | - |
Total Current Liabilities | 11.79 | 11.5 | 10.23 | 14.69 | 32.36 | 1.6 |
Long-Term Debt | 33.38 | 33.43 | 22.59 | - | - | - |
Long-Term Leases | 1.19 | 1.23 | 1.33 | 1.24 | 1.59 | - |
Other Long-Term Liabilities | 11.82 | 23.04 | 15.72 | 35.73 | 0.37 | 15.65 |
Total Long-Term Liabilities | 46.39 | 57.69 | 39.64 | 36.98 | 1.96 | 15.65 |
Total Liabilities | 58.17 | 69.19 | 49.87 | 51.66 | 34.32 | 17.25 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Preferred Stock | - | - | - | - | 164.01 | - |
Common Stock | 0.01 | 0 | 0 | 0 | - | 0 |
Additional Paid-in Capital | 341.85 | 296.72 | 253.65 | 222.44 | 10.03 | - |
Retained Earnings | -329.04 | -330.58 | -279.55 | -249.5 | -186.36 | -16.72 |
Total Common Shareholders' Equity | 12.81 | -33.86 | -25.89 | -27.07 | -176.33 | -16.72 |
Minority Interest | - | - | - | - | - | 250 |
Shareholders' Equity | 12.81 | -33.86 | -25.89 | -27.07 | -176.33 | 233.28 |
Total Liabilities & Equity | 70.98 | 35.33 | 23.97 | 24.6 | 22 | 250.53 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 34.79 | 34.82 | 24.14 | 1.6 | 1.96 | 0.54 |
Net Cash (Debt) | 21.77 | -14.39 | -15.61 | 10.18 | 7.45 | 249.66 |
Net Cash Growth | - | - | - | 36.65% | -97.02% | -0.67% |
Net Cash Per Share | 0.50 | -0.38 | -0.62 | 1.08 | 24.07 | 1139.50 |
Book Value | 12.81 | -33.86 | -25.89 | -27.07 | -176.33 | -16.72 |
Book Value Per Share | 0.29 | -0.89 | -1.02 | -2.88 | -569.52 | -76.30 |
Tangible Book Value | 12.81 | -33.86 | -25.89 | -27.07 | -177.13 | -16.72 |
Tangible Book Value Per Share | 0.29 | -0.89 | -1.02 | -2.88 | -572.12 | -76.30 |